Johnson & Johnson CDR (CAD Hedged)

Ronovo Surgical closed a $67 million Series D funding round led by Johnson & Johnson Development Corporation, bringing the company's 2025 fundraising total to over $100 million.

The combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) achieved 61% three-year survival versus 53% with osimertinib in first-line EGFR-mutated NSCLC treatment.

Johnson & Johnson's Impella CP heart pump showed a 16.3% absolute mortality reduction at 10 years compared to standard care in patients with cardiogenic shock following heart attack.

Predicine has submitted the first module of a premarket approval application to the FDA for PredicineCARE, a urine cell-free DNA next-generation sequencing assay for use as a companion diagnostic in bladder cancer.

Johnson & Johnson discontinued its Phase 2 DAISY trial of nipocalimab combined with anti-TNFα therapy for rheumatoid arthritis after failing to demonstrate sufficient added benefit over monotherapy at 12 weeks.

Johnson & Johnson has terminated development of nipocalimab in combination with anti-TNF-alpha therapies for rheumatoid arthritis after the 12-week Phase 2a DAISY trial failed to demonstrate significant clinical benefits over anti-TNF-alpha therapy alone.

ACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to establish a multi-faceted collaboration framework for developing precision immunotherapies targeting drug-resistant cancers.

Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.

Harbour BioMed has appointed Yajie Li as Chief Medical Officer to lead clinical development and regulatory strategy for the company's immunology and oncology programs.

Johnson & Johnson will invest $2 billion over 10 years to build a 160,000+ square foot manufacturing facility at Fujifilm Biotechnologies' new Holly Springs, North Carolina site.